長指伸筋の筋機能の評価エクスビボと前脛骨筋その場マウスの

Executive Industry Relevance

Accurate assessment of skeletal muscle contractile and passive properties is critical for evaluating disease mechanisms and therapeutic efficacy in preclinical muscle disease models. This method enables direct measurement of force generation, twitch kinetics, and passive stiffness in mouse limb muscles, providing quantitative endpoints for target validation and mechanistic de-risking. By preserving physiological conditions such as oxygenation and blood flow, the approach supports reliable preclinical data generation for go/no-go decisions in neuromuscular and dystrophy-focused discovery programs.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by quantifying changes in twitch force, titanic force, and time-to-peak tension in disease models.
• Operational Value: Provides functional readouts that clarify pathway involvement and support biological de-risking of targets affecting calcium handling, ATP turnover, or sarcolemma integrity.
• Predictive Value: Supports portfolio triage by linking molecular interventions to measurable improvements in contractile and passive muscle properties.

Screening & Assay Development

• Assay Readiness: Generates standardized, reproducible measurements of muscle force and relaxation kinetics suitable for compound screening campaigns.
• Quantitative Output: Delivers normalized force values (e.g., specific twitch and titanic force) and kinetic parameters (TPT, 1/2RT) for cross-study comparison.
• Scalability: Supports evaluation of contralateral muscles and repeated testing cycles to assess fatigue resistance and recovery profiles.

Translational & Preclinical Research

• Disease Relevance: Directly models pathophysiological changes seen in Duchenne muscular dystrophy, including reduced force output and increased passive stiffness.
• Translational Continuity: Enables longitudinal assessment from discovery through preclinical validation by tracking functional decline and rescue.
• Mechanistic De-risking: Distinguishes between contractile deficits and fibrosis-driven stiffness, informing mechanism-based therapeutic strategies.

Pipeline & Workflow Integration

The method fits within the discovery continuum from early target validation to preclinical efficacy testing, offering a functional bridge between molecular phenotypes and whole-muscle physiology.

• Discovery Biology: Supports hypothesis testing by measuring how genetic or pharmacological manipulations affect force generation and relaxation dynamics in intact muscle preparations.
• Screening: Enables assay standardization through controlled stimulation protocols and equilibration periods, ensuring reliable compound evaluation.
• Analytics: Generates key performance indicators including peak force, time-to-peak tension, half-relaxation time, and stress-strain profiles for comparative analysis.
• Translational Research: Connects in vitro findings to tissue-level function by assessing both active and passive properties in disease-relevant systems.
• Enterprise Reuse: Establishes a reusable platform for evaluating multiple muscle groups (EDL, TA) and disease models, reducing redundant method development.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence by reducing mechanistic ambiguity in muscle function assessment.
• Operational Value: Ensures reproducibility through standardized dissection, mounting, and stimulation protocols.
• Strategic Value: Improves capital efficiency by enabling early detection of ineffective candidates, reducing late-stage failure risk.
• Portfolio Impact: Facilitates risk-adjusted advancement decisions based on functional rescue in validated preclinical models.

Implementation Considerations

• Requires expertise in mouse muscle dissection, suture techniques, and physiological monitoring under sterile conditions.
• Dependent on specialized hardware including tissue baths, lever arm systems, stimulators, and DMC-compatible data acquisition software.
• Necessitates cross-team standardization of protocols for stimulation frequency, tension adjustment, and data analysis to ensure reproducibility.
• Involves adaptation considerations when applying the method to different muscle types or disease models with altered morphology or contractility.
• Limited by tissue viability duration, necessitating timely execution of protocols post-dissection to maintain physiological fidelity.

Biopharma FAQs